First patient dosed with PI3K? inhibitor for solid tumours
Drug Discovery World
APRIL 17, 2023
Totus Medicines has dosed its first patient in a Phase I clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations. The study will be conducted in two parts.
52 
Let's personalize your content